Gliomas Clinical Trials

5 recruiting

Gliomas Trials at a Glance

23 actively recruiting trials for gliomas are listed on ClinicalTrialsFinder across 6 cities in 11 countries. The largest study group is Phase 1 with 11 trials, with the heaviest enrollment activity in Bethesda, Sutton, and Columbus. Lead sponsors running gliomas studies include Institute of Cancer Research, United Kingdom, National Cancer Institute (NCI), and Beijing Tiantan Hospital.

Browse gliomas trials by phase

Treatments under study

About Gliomas Clinical Trials

Looking for clinical trials for Gliomas? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Gliomas trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Gliomas clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 23 trials

Recruiting
Phase 1

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Kidney CancersHead and Neck TumorsSmall Cell Lung Cancers+3 more
National Cancer Institute (NCI)120 enrolled1 locationNCT06479811
Recruiting
Phase 1

Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma

GlioblastomaMalignant GliomaRecurrent Glioblastoma+2 more
Beijing Biotech36 enrolled1 locationNCT07551336
Recruiting

Patient Voice in the Treatment of Low-grade Gliomas: Use of Patient-reported Outcomes, Vorasidenib and Radiotherapy Compared

GliomaGlioma of BrainLow Grade Glioma of Brain+2 more
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta90 enrolled1 locationNCT07547163
Recruiting
Not Applicable

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma

Recurrent GlioblastomaRecurrent Gliomas
Alpha Tau Medical LTD.10 enrolled1 locationNCT06910306
Recruiting
Not Applicable

Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors

Brain CancerGliomasRecurrent CNS Tumors+3 more
National Cancer Institute (NCI)80 enrolled1 locationNCT07374692
Recruiting
Phase 2

ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

Diffuse Intrinsic Pontine Gliomas (DIPG)Progressive DIPGRefractory DIPG+2 more
Nationwide Children's Hospital60 enrolled20 locationsNCT06838676
Recruiting
Phase 1Phase 2

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

PheochromocytomaGastrointestinal Neuroendocrine TumorsSomatostatin Receptor Positive+1 more
National Cancer Institute (NCI)66 enrolled1 locationNCT06427798
Recruiting
Early Phase 1

Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas

Gliomas
M.D. Anderson Cancer Center40 enrolled1 locationNCT05804227
Recruiting
Phase 1

A Study of Avutometinib for People With Solid Tumor Cancers

Solid TumorSolid Tumor, AdultNeuroblastoma+12 more
Memorial Sloan Kettering Cancer Center23 enrolled2 locationsNCT06104488
Recruiting
Phase 1Phase 2

5G-PEARL: Paxalisib in Malignant Brain Tumours

Glioblastoma Multiforme (GBM)Malignant Primary Gliomas
Institute of Cancer Research, United Kingdom64 enrolled1 locationNCT07391215
Recruiting
Phase 1Phase 2

5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours

Glioblastoma Multiforme (GBM)Malignant Primary GliomasGlioblastoma Multiform (Grade IV Astrocytoma)+1 more
Institute of Cancer Research, United Kingdom182 enrolled3 locationsNCT06630260
Recruiting
Early Phase 1

Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant Glioma

Adult Gliomas, Mixed
Robert Bok, MD, PhD40 enrolled1 locationNCT05851378
Recruiting
Not Applicable

Developing Fast Pediatric Imaging

Pediatric Low-grade Gliomas
Boston Children's Hospital300 enrolled3 locationsNCT03761121
Recruiting

AI-assisted Diagnosis of Malignant Brain Tumors

Brain Metastases, AdultLymphomaGliomas+1 more
Second Affiliated Hospital, School of Medicine, Zhejiang University3,000 enrolled2 locationsNCT07198256
Recruiting
Phase 1Phase 2

Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection

GBMHigh-Grade GliomasBrain Gliomas
Dushu Lake Hospital Affiliated to Soochow University25 enrolled1 locationNCT06018363
Recruiting
Phase 1

Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations

Gliomas Harboring IDH1 and/or IDH2 Mutations
Hutchmed52 enrolled1 locationNCT07025018
Recruiting
Not Applicable

Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) in Glioma (WHO G3-G4) Progression

GlioblastomaGrade III GliomaHigh-Grade Gliomas+1 more
Medical University of Warsaw35 enrolled2 locationsNCT06975332
Recruiting
Phase 1

5G-EMERALD: Amivantamab in Malignant Brain Tumours

Glioblastoma Multiforme (GBM)Malignant Primary GliomasGlioblastoma Multiform (Grade IV Astrocytoma)+1 more
Institute of Cancer Research, United Kingdom12 enrolled2 locationsNCT06632236
Recruiting
Early Phase 1

A Single-arm, Open, Exploratory Clinical Study of Allogeneic CAR-T Cells in the Treatment of Relapsed/Refractory Brain Gliomas With Positive CD70 Expression

Gliomas
JIANG LONGWEI3 enrolled1 locationNCT06828341
Recruiting
Phase 1

Safety and Efficacy Study for DC Vaccine in Recurrent or Progressive High-grade Gliomas

WHO Grade III GliomasWHO Grade IV Gliomas
Beijing Tiantan Hospital12 enrolled1 locationNCT06253234